Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)

CAPS Rating: 1 out of 5

The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs.

Results 1 - 12 of 12

Recs

1
Member Avatar zzlangerhans (99.85) Submitted: 11/5/2014 7:12:59 PM : Underperform Start Price: $1.68 SNSS Score: -49.21

It's been two years since I laid out my thesis for the failure of the VALOR trial at http://caps.fool.com/Pitch/SNSS/6511180/its-clear-that-2012-has-minted.aspx , and almost a month since my prediction came true after countless delays and footdragging by Sunesis. The initial extreme negative reaction that took the share price down to 1.05 and a market cap of 64M was justified, as the company will likely be reporting an asset balance of 35M or less in their quarterly earnings conference on Monday. I expected that the share price would quickly slip below a dollar as the harsh truth sunk in that vosaroxin's prospects are beyond grim and Sunesis has an anemic pipeline from which to generate a follow up act.

Despite my pessimism, Sunesis stock has rebounded with a near double this month. Did traders actually swallow the boilerplate tripe about the subset analysis censored for stem cell transplantation, or the chest beating about regulatory submissions despite the trial failure? Hard to know. This is an easy red thumb for me as I watched Sunesis boast a completely undeserved market cap for years despite the almost inveitable upcoming failure of VALOR.

Recs

0
Member Avatar pchop123 (80.36) Submitted: 7/31/2014 12:41:04 PM : Underperform Start Price: $6.63 SNSS Score: +68.47

overpriced

Recs

0
Member Avatar motleyflyer (< 20) Submitted: 1/30/2013 7:21:31 AM : Outperform Start Price: $4.97 SNSS Score: -76.19

Pharma Research

Recs

0
Member Avatar SnarkyApple (53.73) Submitted: 9/27/2012 4:32:36 PM : Underperform Start Price: $5.67 SNSS Score: +99.01

Shenanigans.

Recs

0
Member Avatar theMANzalone (51.56) Submitted: 3/14/2012 4:05:12 PM : Outperform Start Price: $2.45 SNSS Score: -43.98

2013 will kick into gear

Recs

0
Member Avatar DanishDynamite (< 20) Submitted: 7/22/2011 4:38:21 AM : Outperform Start Price: $2.04 SNSS Score: -29.23

Finally, found its price range, before we reach a yes or no, it will spike on phase III news.

Recs

0
Member Avatar stemcells2011 (87.92) Submitted: 3/1/2011 10:56:34 AM : Outperform Start Price: $2.07 SNSS Score: -33.04

Very bullish long term.

Recs

0
Member Avatar archingstocks (< 20) Submitted: 1/10/2011 5:23:50 PM : Outperform Start Price: $2.97 SNSS Score: -76.97

Well funded, well staffed, good drug

Recs

2
Member Avatar akshara3000 (< 20) Submitted: 1/5/2011 6:10:19 PM : Outperform Start Price: $3.00 SNSS Score: -76.82

If phase 3 trial info is released midterm through the study, and it is as positive and consistent as previous results, the stock will jump remarkably, especially after being beaten down so badly since mid 2010. This thing could easily double or triple in a years time, since there is no reason not to believe that phase 3 results will be outstanding. That does not guarantee approval, but there should be money to be made well before that stage of the process. 25k shares at 66 cents and I will hold long term

Recs

0
Member Avatar 1997amer (< 20) Submitted: 1/1/2011 5:05:18 PM : Outperform Start Price: $3.12 SNSS Score: -82.01

It is an oncology orphan drug!!! very likely wii be approved even with 4 -5 weeks improved survival.

Recs

0
Member Avatar motleyjmw (< 20) Submitted: 1/19/2007 1:48:31 PM : Outperform Start Price: $30.00 SNSS Score: -145.69

Biogen Idec is a beneficial owner

Recs

0
Member Avatar theminc (< 20) Submitted: 10/6/2006 9:28:50 PM : Underperform Start Price: $30.00 SNSS Score: +154.79

Early in the IPO. Solid company with a lot of bright minds. Results of clinical trial results will determine level of success.

Results 1 - 12 of 12

Featured Broker Partners


Advertisement